Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Phipps

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
The Journal of the Acoustical Society of America|April 10, 2008
Acoustic energy harvesting using an electromechanical Helmholtz resonatorFei Liu, Alex Phipps, Stephen Horowitz, et al.
Scientific Reports|August 13, 2021
Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patientsAleksandra E Kmieciak, Liam V Brown, Mark C Coles, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2018
Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next LevelLucy Hutchinson, Bernhard Steiert, Antoine Soubret, et al.
Clinical Pharmacology and Therapeutics|December 12, 2017
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentYumi Cleary, Michael Gertz, Peter N Morcos, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
Clinical Pharmacology and Therapeutics|June 24, 2020
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell TumorKevin Smart, Ann-Marie Bröske, Dominik Rüttinger, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 8, 2021
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-MakingNassim Djebli, Vincent Buchheit, Neil Parrott, et al.
Investigational New Drugs|January 19, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsGeorgina Meneses-Lorente, Darren Bentley, Elena Guerini, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
The Journal of the Acoustical Society of America|April 10, 2008
Acoustic energy harvesting using an electromechanical Helmholtz resonatorFei Liu, Alex Phipps, Stephen Horowitz, et al.
Scientific Reports|August 13, 2021
Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patientsAleksandra E Kmieciak, Liam V Brown, Mark C Coles, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 15, 2018
Models and Machines: How Deep Learning Will Take Clinical Pharmacology to the Next LevelLucy Hutchinson, Bernhard Steiert, Antoine Soubret, et al.
Clinical Pharmacology and Therapeutics|December 12, 2017
Model-Based Assessments of CYP-Mediated Drug-Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical DevelopmentYumi Cleary, Michael Gertz, Peter N Morcos, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy SubjectsPeter N Morcos, Elena Guerini, Neil Parrott, et al.
Clinical Pharmacology and Therapeutics|June 24, 2020
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell TumorKevin Smart, Ann-Marie Bröske, Dominik Rüttinger, et al.
European Journal of Drug Metabolism and Pharmacokinetics|September 8, 2021
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-MakingNassim Djebli, Vincent Buchheit, Neil Parrott, et al.
Investigational New Drugs|January 19, 2021
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumorsGeorgina Meneses-Lorente, Darren Bentley, Elena Guerini, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2023
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerationsGeorgina Meneses-Lorente, Elena Guerini, Francois Mercier, et al.
Pageof 4